Press release
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
Clinical trials will advance treatment of COVID-19 infection. BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a
About this update from Sinovac Biotech, Ltd.
[{"type":"text","content":"\nClinical trials will advance treatment of COVID-19 infection.\n\n\n BEIJING--(BUSINESS WIRE)--\nSinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.\n\n\nSINOVAC’s SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023. The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China.\n\n\nThe phase II clinical trial is a multicenter, randomized, double-blind, placebo-controlled study. It is expected to enroll 150 patients aged 18 and above with mild to moderate COVID-19 infection from nearly 20 medical institutions in China. Participants will be randomly assigned to groups receiving different dosages of SA55 Injection or placebo to evaluate its ability to decrease SARS-CoV-2 virus loads and alleviate clinical symptoms, while assessing its safety. Preliminary results are anticipated by the year’s end.\n\n\nMr. Weidong Yin, Chairman, President and CEO of SINOVAC, said: “After providing over 2.9 billion doses of SINOVAC’s COVID-19 vaccines to the world, we still expect to address the fast-developing COVID-19 virus mutations with a cutting-edge technology. The neutralizing antibody with broad-spectrum effectiveness is our new tool in our ongoing battle against the persistent threat to human health posed by the COVID-19 virus.”\n\n\n“We hope that our SA55 injection can continuously make valuable contributions to COVID-19 prevention and control efforts, not only in China, but also globally,” Mr. Yin added.\n\n\nThe broad-spectrum neutralizing antibody SA55 was founded by a research team led by Dr. Xiaoliang Xie, academician of the Chinese Academy of Sciences and Dr. Yunlong Cao, researcher at Peking University’s Biomedical Pioneering Innovation Center. SA55 injection is a fully humanized antibody, which is screened from the blood of recovered SARS patients who have received three doses of COVID-19 vaccine, and then recombinantly e...